Abstract
According to the National Institute of Neurological Disorders and Stroke (NIH), there are found to be 488 neurological disorders present in the world at the time of writing, ranging from acid lipase disease to Zellweger syndrome [1]. No book chapter is equipped to tackle all of these in detail; however, it will focus upon the five major neurological diseases: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis. The chapter will begin by summarising the epidemiology, pathology and disease susceptibilities for each of these five major neurological diseases. The chapter will then look in detail at generating patient-specific cell lines for personalised medicine, genome editing and the differentiation protocols necessary for cell replacement therapy related to the aforementioned neurodegenerative diseases. This chapter will then look at the alternative cell sources that have been used as existing and current cell therapeutic strategies before summarising with the advantages and constraints of stem cells in research and clinical translation. Finally, the chapter will conclude on the current research findings with a particular focus on patient-derived research in Parkinson’s disease and how different therapeutic strategies can be targeted at different neurological diseases focusing on – Parkinson’s disease and multiple sclerosis – before summarising on the challenges for stem cell therapy in neurological disorders: from bench to the bedside.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
http://www.ninds.nih.gov/disorders/disorder_index.htm. Accessed 1 Aug 2013
Holtzman DM, Morris JC, Goate AM (2011) Alzheimer’s disease: the challenge of the second century. Sci Transl Med 3, 77 sr71. doi:10.1126/scitranslmed.3002369
Wimo A, Prince M (2010) World Alzheimer report 2010: the global economic impact of Dementia. Alzheimer’s Dis Int 1–56
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259. doi:10.1007/bf00308809
Sherrington R et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375(6534):754–760
Levy-Lahad E et al (1995) Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 269(5226):973–977
Goate A et al (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349(6311):704–706
Scheuner D et al (1996) Secreted amyloid [beta]-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 2(8):864–870
Kumar-Singh S et al (2006) Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40. Hum Mutat 27(7):686–695
Bentahir M et al (2006) Presenilin clinical mutations can affect γ-secretase activity by different mechanisms. J Neurochem 96(3):732–742
De Strooper B et al (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391(6665):387–390
Braak H, Braak E (2000) Pathoanatomy of Parkinson’s disease. J Neurol 247:II3–II10
Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A (2013) The current and projected economic burden of Parkinson’s disease in the United States. Mov Disord 28:311–318. doi:10.1002/mds.25292
Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114:2283–2301. doi:10.1093/brain/114.5.2283
Campion D et al (1999) Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 65(3):664–670
Genin E et al (2011) APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 16(9):903–907
Farrer LA et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein e genotype and Alzheimer disease: a meta-analysis. JAMA 278(16):1349–1356
Mounsey RB, Teismann P (2010) Mitochondrial dysfunction in Parkinson’s disease: pathogenesis and neuroprotection. Parkinson’s Dis 2011(Article ID 617472): 18 pages
Klein C, Westenberger A (2012) Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med 2(1)
Kuusisto E, Parkkinen L, Alafuzoff I (2003) Morphogenesis of Lewy bodies: dissimilar incorporation of [alpha]-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 62:1241–1253
Wakabayashi K, Tanji K, Mori F, Takahashi H (2007) The Lewy body in Parkinson’s disease: molecules implicated in the formation and degradation of α-synuclein aggregates. Neuropathology 27:494–506
Maries E et al (2003) The role of [alpha]-synuclein in Parkinson’s disease: insights from animal models. Nat Rev Neurosci 4(9):727–738
Singleton AB et al (2003) {alpha}-Synuclein locus triplication causes Parkinson’s disease. Science 302(5646):841
Ibáñez P et al (2004) Causal relation between A-synuclein locus duplication as a cause of familial Parkinson’s disease. The Lancet 364(9440):1169–1171
Miyake Y et al (2012) SNCA polymorphisms, smoking, and sporadic Parkinson’s disease in Japanese. Parkinsonism Relat Disord 18(5):557–561
Pan F et al (2012) SNP rs356219 of the α-synuclein (SNCA) gene is associated with Parkinson’s disease in a Chinese Han population. Parkinsonism Relat Disord 18(5):632–634
Westerlund M, Hoffer B, Olson L (2010) Parkinson’s disease: exit toxins, enter genetics. Prog Neurobiol 90(2):146–156
MacDonald ME et al (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983. doi:http://dx.doi.org/10.1016/0092-8674(93)90585-E
Estrada Sánchez AM, Mejía-Toiber J, Massieu L (2008) Excitotoxic neuronal death and the pathogenesis of Huntington’s disease. Arch Med Res 39:265–276. doi:http://dx.doi.org/10.1016/j.arcmed.2007.11.011
Reiner A et al (1988) Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci 85:5733–5737
Lobsiger CS, Cleveland DW (2007) Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci 10(11):1355–1360
Langbehn DR et al (2004) A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet 65:267–277.doi:10.1111/j.1399-0004.2004.00241.x
Rosenblatt A et al (2006) The association of CAG repeat length with clinical progression in Huntington disease. Neurology 66:1016–1020
Walker FO (2007) Huntington’s disease. Lancet 369:218–228. doi:http://dx.doi.org/10.1016/S0140-6736(07)60111-1
Rice CM, Kemp K, Wilkins A, Scolding NJ (2013) Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. Lancet 382:1204–1213. doi:http://dx.doi.org/10.1016/S0140-6736(13)61810-3
Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502–1517. doi:http://dx.doi.org/10.1016/S0140-6736(08)61620-7
Olsson T et al (1990) Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest 86:981–985. doi:10.1172/jci114800
Disanto G et al (2013) Epstein–Barr virus, latitude and multiple sclerosis. Mult Scler J 19:362–365. doi:10.1177/1352458512451942
Simpson S, Blizzard L, Otahal P, Van der Mei I, Taylor B (2011) Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 82:1132–1141. doi:10.1136/jnnp.2011.240432
Orton S-M et al (2006) Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 5:932–936. doi:http://dx.doi.org/10.1016/S1474-4422(06)70581-6
Stüve O, Oksenberg J (2010) In: Pagon RA, Adam MP, Bird TD (eds) GeneReviews
Barcellos LF et al (2006) Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 15:2813–2824. doi:10.1093/hmg/ddl223
Alcina A et al (2012) Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations. PLoS One 7:e29819. doi:10.1371/journal.pone.0029819
Pesiridis GS, Lee VM-Y, Trojanowski JQ (2009) Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum Mol Genet 18:R156–R162. doi:10.1093/hmg/ddp303
Kiernan MC et al (2011) Amyotrophic lateral sclerosis. Lancet 377:942–955. doi:http://dx.doi.org/10.1016/S0140-6736(10)61156-7
Orenstein SJ et al (2013) Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 16(4):394–406
Friedman LG et al (2012) Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α-synuclein and LRRK2 in the brain. J Neurosci 32(22):7585–7593
Badiola N et al (2011) Tau enhances A-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One 6(10):e26609
Clinton LK et al (2010) Synergistic interactions between ABeta, Tau, and A-Synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 30(21):7281–7289
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676
Gurdon JB (1962) The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. J Embryol Exp Morphol 10:622–640
Takahashi K et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872
Yu J et al (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917–1920. doi:10.1126/science.1151526
Niknejad H, Deihim T, Ahmadiani A, Jorjani M, Peirovi H (2012) Permanent expression of midbrain dopaminergic neurons traits in differentiated amniotic epithelial cells. Neurosci Lett 506(1):22–27
Yan X et al (2009) iPS cells reprogrammed from human mesenchymal-like stem/progenitor cells of dental tissue origin. Stem Cells Dev 19:469–480
Narsinh KH et al (2010) Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors. Nat Protoc 6:78–88
Ye Z et al (2009) Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 114:5473–5480. doi:10.1182/blood-2009-04-217406
Yuin-Han L et al (2009) Generation of induced pluripotent stem cells from human blood. Blood 113:5476–5479
Brown ME et al (2010) Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. PLoS One 5:e11373
Zhou T et al (2012) Generation of human induced pluripotent stem cells from urine samples. Nat Protocols 7:2080–2089. doi:http://www.nature.com/nprot/journal/v7/n12/abs/nprot.2012.115.html#supplementary-information
Okita K, Ichisaka T, Yamanaka S (2007) Generation of germline-competent induced pluripotent stem cells. Nature 448:313–317
Yu J et al (2009) Human induced pluripotent stem cells free of vector and transgene sequences. Science 324:797–801. doi:10.1126/science.1172482
Zhou W, Freed CR (2009) Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 27:2667–2674. doi:10.1002/stem.201
Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M (2009) Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B 85:348–362
Jia F et al (2010) A nonviral minicircle vector for deriving human iPS cells. Nat Methods 7:197–199. doi:http://www.nature.com/nmeth/journal/v7/n3/suppinfo/nmeth.1426_S1.html
Okita K et al (2011) A more efficient method to generate integration-free human iPS cells. Nat Methods 8:409–412. doi:http://www.nature.com/nmeth/journal/v8/n5/abs/nmeth.1591.html#supplementary-information
Park HY et al (2012) Efficient generation of virus-free iPS cells using liposomal magnetofection. PLoS One 7:e45812. doi:10.1371/journal.pone.0045812
Rais Y et al (2013) Deterministic direct reprogramming of somatic cells to pluripotency. Nature 502: 65–70. doi:10.1038/nature12587, http://www.nature.com/nature/journal/v502/n7469/abs/nature12587.html#supplementary-information
Kaji K et al (2009) Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458:771–775. doi:http://www.nature.com/nature/journal/v458/n7239/suppinfo/nature07864_S1.html
Woltjen K et al (2009) piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458:766–770. doi:http://www.nature.com/nature/journal/v458/n7239/suppinfo/nature07863_S1.html
Sommer CA et al (2010) Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells 28:64–74. doi:10.1002/stem.255
Kim D et al (2009) Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 4:472–476. doi:http://dx.doi.org/10.1016/j.stem.2009.05.005
Warren L et al (2010) Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7:618–630. doi:http://dx.doi.org/10.1016/j.stem.2010.08.012
Miyoshi N et al (2011) Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 8:633–638
Hou P et al (2013) Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 341:651–654. doi:10.1126/science.1239278
Martins-Taylor K, Xu R-H (2012) Concise review: genomic stability of human induced pluripotent stem cells. Stem Cells 30:22–27. doi:10.1002/stem.705
Baker DEC et al (2007) Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol 25:207–215. doi:http://www.nature.com/nbt/journal/v25/n2/suppinfo/nbt1285_S1.html
Ben-David U, Benvenisty N (2011) The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 11:268–277
Lanford RE et al (2011) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327:198–201. doi:10.1126/science.1178178
Li Y, Masaki T, Yamane D, McGivern DR, Lemon SM (2013) Competing and noncompeting activities of miR-122 and the 5′ exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc Natl Acad Sci 110:1881–1886. doi:10.1073/pnas.1213515110
Grinnemo K-H, Sylvén C, Hovatta O, Dellgren G, Corbascio M (2008) Immunogenicity of human embryonic stem cells. Cell Tissue Res 331:67–78
Palmisano I et al (2012) Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proc Natl Acad Sci 109:E2284–E2293. doi:10.1073/pnas.1202174109
Toivonen S et al (2013) Comparative analysis of targeted differentiation of human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells reveals variability associated with incomplete transgene silencing in retrovirally derived hiPSC lines. Stem Cells Transl Med 2:83–93. doi:10.5966/sctm.2012-0047
Hussein SM et al (2011) Copy number variation and selection during reprogramming to pluripotency. Nature 471:58–62. doi:http://www.nature.com/nature/journal/v471/n7336/abs/10.1038-nature09871-unlocked.html#supplementary-information
Gore A et al (2011) Somatic coding mutations in human induced pluripotent stem cells. Nature 471:63–67. doi:http://www.nature.com/nature/journal/v471/n7336/abs/10.1038-nature09805-unlocked.html#supplementary-information
Kim K et al (2010) Epigenetic memory in induced pluripotent stem cells. Nature 467:285–290. doi:http://www.nature.com/nature/journal/v467/n7313/abs/nature09342.html#supplementary-information
Sommer CA et al (2012) Residual expression of reprogramming factors affects the transcriptional program and epigenetic signatures of induced pluripotent stem cells. PLoS One 7:e51711. doi:10.1371/journal.pone.0051711
Byers B et al (2011) SNCA triplication Parkinson’s patient’s iPSC-derived DA neurons accumulate a-synuclein and are susceptible to oxidative stress. PLoS One 6:e26159
Devine MJ et al (2011) Parkinson’s disease induced pluripotent stem cells with triplication of the A-synuclein locus. Nat Commun 2:440
Soldner F et al (2011) Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146:318–331
Reinhardt P et al (2013) Genetic correction of a LRRK2 mutation in human iPSCs links Parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 12:354–367. doi:http://dx.doi.org/10.1016/j.stem.2013.01.008
Liu G-H et al (2012) Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 491:603–607. doi:http://www.nature.com/nature/journal/v491/n7425/abs/nature11557.html#supplementary-information
An MC et al (2012) Genetic correction of Huntington’s disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11:253–263. doi:http://dx.doi.org/10.1016/j.stem.2012.04.026
Liu G-H et al (2011) Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 472:221–225. doi:http://www.nature.com/nature/journal/v472/n7342/abs/10.1038-nature09879-unlocked.html#supplementary-information
Liu G-H et al (2011) Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell 8:688–694. doi:http://dx.doi.org/10.1016/j.stem.2011.04.019
Howden SE et al (2011) Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy. Proc Natl Acad Sci 108:6537–6542. doi:10.1073/pnas.1103388108
Hockemeyer D et al (2009) Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 27: 851–857. doi:10.1038/nbt.1562, http://www.nature.com/nbt/journal/v27/n9/abs/nbt.1562.html#supplementary-information
Song H, Chung S-K, Xu Y (2010) Modeling disease in human ESCs using an efficient BAC-based homologous recombination system. Cell stem cell 6:80–89. doi:http://dx.doi.org/10.1016/j.stem.2009.11.016
Hockemeyer D et al (2011) Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 29:731–734. doi:http://www.nature.com/nbt/journal/v29/n8/abs/nbt.1927.html#supplementary-information
Cong L et al (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823. doi:10.1126/science.1231143
Gruenert DC, Sargent RG (2012) Virus-mediated genetic surgery: homologous recombination with a little [ldquo]helper[rdquo] from my friends. Mol Ther Nucleic Acids 1:e2. doi:10.1038/mtna.2011.7
Ramirez CL et al (2008) Unexpected failure rates for modular assembly of engineered zinc fingers. Nat Methods 5:374–375. doi:http://www.nature.com/nmeth/journal/v5/n5/suppinfo/nmeth0508-374_S1.html
Ma N et al (2013) TALEN-mediated gene correction in integration-free β-thalassemia iPSCs. J Biol Chem. doi:10.1074/jbc.M113.496174
Fu Y et al (2013) High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31: 822–826. doi:10.1038/nbt.2623, http://www.nature.com/nbt/journal/v31/n9/abs/nbt.2623.html#supplementary-information
Ran FA, HSU et al (2013) Double-nicking by RNA-guided CRISPR CAS9 for enhanced genome editing specificity. Cell 154(6):1380–1389
Chung CY et al (2013) Identification and rescue of α-synuclein toxicity in Parkinson patient–derived neurons. Science. doi:10.1126/science.1245296
Ring KL et al (2012) Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell 11:100–109. doi:http://dx.doi.org/10.1016/j.stem.2012.05.018
Vierbuchen T et al (2010) Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463:1035–1041
Jakovcevski I, Filipovic R, Mo Z, Rakic S, Zecevic N (2009) Oligodendrocyte development and the onset of myelination in the human fetal brain. Frontiers Neuroanat 3. doi:10.3389/neuro.05.005.2009
Pang ZP et al (2011) Induction of human neuronal cells by defined transcription factors. Nature 476:220–223. doi:http://www.nature.com/nature/journal/v476/n7359/abs/nature10202.html#supplementary-information
Ambasudhan R et al (2011) Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions. Cell Stem Cell 9:113–118. doi:http://dx.doi.org/10.1016/j.stem.2011.07.002
Yoo AS et al (2011) MicroRNA-mediated conversion of human fibroblasts to neurons. Nature 476:228–231. doi:http://www.nature.com/nature/journal/v476/n7359/abs/nature10323.html#supplementary-information
Qiang L et al (2011) Directed conversion of Alzheimer’s disease patient skin fibroblasts into functional neurons. Cell 146:359–371. doi:http://dx.doi.org/10.1016/j.cell.2011.07.007
Caiazzo M et al (2011) Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 476:224–227. doi:http://www.nature.com/nature/journal/v476/n7359/abs/nature10284.html#supplementary-information
Pfisterer U et al (2011) Direct conversion of human fibroblasts to dopaminergic neurons. Proc Natl Acad Sci U S A 108:10343–10348. doi:10.1073/pnas.1105135108
Addis RC et al (2011) Efficient conversion of astrocytes to functional midbrain dopaminergic neurons using a single polycistronic vector. PLoS One 6:e28719. doi:10.1371/journal.pone.0028719
Kim J et al (2011) Functional integration of dopaminergic neurons directly converted from mouse fibroblasts. Cell Stem Cell 9:413–419. doi:http://dx.doi.org/10.1016/j.stem.2011.09.011
Liu X et al (2012) Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. Cell Res 22:321–332. doi:http://www.nature.com/cr/journal/v22/n2/suppinfo/cr2011181s1.html
Meng F, Wang X, Gu P, Wang Z, Guo W (2013) Induction of retinal ganglion-like cells from fibroblasts by adenoviral gene delivery. Neuroscience 250:381–393. doi:http://dx.doi.org/10.1016/j.neuroscience.2013.07.001
Son EY et al (2011) Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell 9:205–218. doi:http://dx.doi.org/10.1016/j.stem.2011.07.014
Kim J et al (2011) Direct reprogramming of mouse fibroblasts to neural progenitors. Proc Natl Acad Sci 108:7838–7843. doi:10.1073/pnas.1103113108
Thier M et al (2012) Direct conversion of fibroblasts into stably expandable neural stem cells. Cell Stem Cell 10:473–479. doi:http://dx.doi.org/10.1016/j.stem.2012.03.003
Han DW et al (2012) Direct reprogramming of fibroblasts into neural stem cells by defined factors. Cell Stem Cell 10:465–472. doi:http://dx.doi.org/10.1016/j.stem.2012.02.021
Lujan E, Chanda S, Ahlenius H, Südhof TC, Wernig M (2012) Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. Proc Natl Acad Sci 109:2527–2532. doi:10.1073/pnas.1121003109
Sheng C et al (2012) Direct reprogramming of Sertoli cells into multipotent neural stem cells by defined factors. Cell Res 22:208–218. doi:http://www.nature.com/cr/journal/v22/n1/suppinfo/cr2011175s1.html
He X et al (1989) Expression of a large family of POU-domain regulatory genes in mammalian brain development. Nature 340:35–42
Crompton LA et al (2013) Stepwise, non-adherent differentiation of human pluripotent stem cells to generate basal forebrain cholinergic neurons via hedgehog signaling. Stem Cell Res 11:1206–1221. doi:http://dx.doi.org/10.1016/j.scr.2013.08.002
Delli Carri A et al (2013) Human pluripotent stem cell differentiation into authentic striatal projection neurons. Stem Cell Rev Rep 9:461–474. doi:10.1007/s12015-013-9441-8
Delli Carri A et al (2013) Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development 140:301–312. doi:10.1242/dev.084608
Kriks S et al (2011) Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 480(7378):547–551
Amoroso MW et al (2013) Accelerated high-yield generation of limb-innervating motor neurons from human stem cells. J Neurosci 33:574–586. doi:10.1523/jneurosci.0906-12.2013
Sundberg M et al (2011) A xeno-free culturing protocol for pluripotent stem cell-derived oligodendrocyte precursor cell production. Regen Med 6:449–460. doi:10.2217/rme.11.36
Kirkeby A et al (2012) Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep 1:703–714
Alexander T, Nolte C, Krumlauf R (2009) Hox genes and segmentation of the hindbrain and axial skeleton. Ann Rev Cell Dev Biol 25:431–456. doi:10.1146/annurev.cellbio.042308.113423
Millet S et al (1999) A role for Gbx2 in repression of Otx2 and positioning the mid/hindbrain organizer. Nature 401:161–164
Brodski C et al (2003) Location and size of dopaminergic and serotonergic cell populations are controlled by the position of the midbrain–hindbrain organizer. J Neurosci 23:4199–4207
Mishima Y, Lindgren AG, Chizhikov VV, Johnson RL, Millen KJ (2009) Overlapping function of Lmx1a and Lmx1b in anterior hindbrain roof plate formation and cerebellar growth. J Neurosci 29:11377–11384. doi:10.1523/jneurosci.0969-09.2009
Liang X et al (2011) Isl1 Is required for multiple aspects of motor neuron development. Mol Cell Neurosci 47:215–222. doi:http://dx.doi.org/10.1016/j.mcn.2011.04.007
Dasen JS, De Camilli A, Wang B, Tucker PW, Jessell TM (2008) Hox repertoires for motor neuron diversity and connectivity gated by a single accessory factor, FoxP1. Cell 134:304–316. doi:http://dx.doi.org/10.1016/j.cell.2008.06.019
Rousso DL, Gaber ZB, Wellik D, Morrisey EE, Novitch BG (2008) Coordinated actions of the forkhead protein Foxp1 and Hox proteins in the columnar organization of spinal motor neurons. Neuron 59:226–240
Binamé F, Sakry D, Dimou L, Jolivel V, Trotter J (2013) NG2 regulates directional migration of oligodendrocyte precursor cells via Rho GTPases and polarity complex proteins. J Neurosci 33:10858–10874. doi:10.1523/jneurosci.5010-12.2013
Mabie PC et al (1997) Bone morphogenetic proteins induce astroglial differentiation of oligodendroglial–astroglial progenitor cells. J Neurosci 17:4112–4120
Thomson JA et al (1998) Embryonic stem cell lines derived from human blastocysts. Science 282:1145–1147. doi:10.1126/science.282.5391.1145
Becker AJ, McCulloch EA, Till JE (1963) Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 197:452–454
Moss FP, Leblond CP (1971) Satellite cells as the source of nuclei in muscles of growing rats. Anat Rec 170:421–435. doi:10.1002/ar.1091700405
Mauro A (1961) Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 9:493–495. doi:10.1083/jcb.9.2.493
Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP (1968) Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 6:230–247
Broxmeyer HE et al (1990) Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells. Int J Cell Cloning 8:76–91. doi:10.1002/stem.5530080708
Emerson SG et al (1985) Purification of fetal hematopoietic progenitors and demonstration of recombinant multipotential colony-stimulating activity. J Clin Invest 76:1286–1290. doi:10.1172/jci112087
Reynolds B, Weiss S (1992) Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255:1707–1710
Zuk PA et al (2002) Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13:4279–4295. doi:10.1091/mbc.E02-02-0105
Zuk PA et al (2001) Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7:211–228
De Coppi P et al (2007) Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 25:100–106. doi:http://www.nature.com/nbt/journal/v25/n1/suppinfo/nbt1274_S1.html
Zhao Y et al (2009) Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice. PLoS One 4:e4226. doi:10.1371/journal.pone.0004226
Zhao Y et al (2012) Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med 10:3
Neirinckx V, Marquet A, Coste C, Rogister B, Wislet-Gendebien S (2013) Adult bone marrow neural crest stem cells and mesenchymal stem cells are not able to replace lost neurons in acute MPTP-lesioned mice. PLoS One 8:e64723. doi:10.1371/journal.pone.0064723
Khoo MLM, Tao H, Meedeniya ACB, Mackay-Sim A, Ma DDF (2011) Transplantation of neuronal-primed human bone marrow mesenchymal stem cells in hemiparkinsonian rodents. PLoS One 6:e19025. doi:10.1371/journal.pone.0019025
Wislet-Gendebien S et al (2012) In vivo tumorigenesis was observed after injection of in vitro expanded neural crest stem cells isolated from adult bone marrow. PLoS One 7:e46425. doi:10.1371/journal.pone.0046425
Xiong N et al (2010) Long-term efficacy and safety of human umbilical cord mesenchymal stromal cells in rotenone-induced hemiparkinsonian rats. Biol Blood Marrow Transplant 16:1519–1529
Somoza R, Juri C, Baes M, Wyneken U, Rubio FJ (2010) Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson’s disease. Biol Blood Marrow Transplant 16:1530–1540
Glavaski-Joksimovic A et al (2010) Glial cell line-derived neurotrophic factor–secreting genetically modified human bone marrow-derived mesenchymal stem cells promote recovery in a rat model of Parkinson’s disease. J Neurosci Res 88:2669–2681. doi:10.1002/jnr.22435
Whone AL, Kemp K, Sun M, Wilkins A, Scolding NJ (2012) Human bone marrow mesenchymal stem cells protect catecholaminergic and serotonergic neuronal perikarya and transporter function from oxidative stress by the secretion of glial-derived neurotrophic factor. Brain Res 1431:86–96. doi:http://dx.doi.org/10.1016/j.brainres.2011.10.038
Kingham P et al (2013) Stimulating the neurotrophic and angiogenic properties of human adipose derived stem cells enhances nerve repair. Stem Cells 23(7):741–754
Dunnett SB, Bjo¨rklund A, Stenevi U, Iversen SD (1981) Grafts of embryonic substantia nigra reinnervating the ventrolateral striatum ameliorate sensorimotor impairments and akinesia in rats with 6-OHDA lesions of the nigrostriatal pathway. Brain Res 229:209–217. doi:http://dx.doi.org/10.1016/0006-8993(81)90759-9
Dunnett SB, Isacson O, Sirinathsinghji DJS, Clarke DJ, Björklund A (1988) Striatal grafts in rats with unilateral neostriatal lesions—III. Recovery from dopamine-dependent motor asymmetry and deficits in skilled paw reaching. Neuroscience 24:813–820. doi:http://dx.doi.org/10.1016/0306-4522(88)90069-3
Zetterström T et al (1986) In vivo measurement of spontaneous release and metabolism of dopamine from intrastriatal nigral grafts using intracerebral dialysis. Brain Res 362:344–349. doi:http://dx.doi.org/10.1016/0006-8993(86)90460-9
Björklund A, Stenevi U, Dunnett SB, Iversen SD (1981) Functional reactivation of the deafferented neostriatum by nigral transplants. Nature 289:497–499
Björklund A, Dunnett SB, Stenevi U, Lewis ME, Iversen SD (1980) Reinnervation of the denervated striatum by substantia nigra transplants: Functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res 199:307–333. doi:http://dx.doi.org/10.1016/0006-8993(80)90692-7
Lindvall O, Rehncrona S, Brundin P et al (1989) Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson’s disease: a detailed account of methodology and a 6-month follow-up. Arch Neurol 46:615–631. doi:10.1001/archneur.1989.00520420033021
Lindvall O et al (1990) Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease. Science 247:574–577. doi:10.1126/science.2105529
Freed CR et al (1992) Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson’s disease. N Engl J Med 327:1549–1555. doi:10.1056/NEJM199211263272202
Widner H et al (1992) Bilateral fetal mesencephalic grafting in two patients with Parkinsonism induced by 1-methyl-4-phenyl-L,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 327:1556–1563. doi:10.1056/NEJM199211263272203
Spencer DD et al (1992) Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson’s disease. N Engl J Med 327:1541–1548. doi:10.1056/NEJM199211263272201
Kordower JH et al (1995) Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. N Engl J Med 332:1118–1124. doi:10.1056/NEJM199504273321702
Peschanski M et al (1994) Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson’s disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 117:487–499. doi:10.1093/brain/117.3.487
Henderson BH, Clough CG, Hughes RC, Hitchcock ER, Kenny BG (1991) IMplantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson’s disease. Arch Neurol 48:822–827. doi:10.1001/archneur.1991.00530200062020
Freed CR et al (2001) Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 344:710–719. doi:10.1056/NEJM200103083441002
Olanow CW et al (2003) A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 54:403–414. doi:10.1002/ana.10720
Barker RA, Barrett J, Mason SL, Björklund A (2013) Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson’s disease. Lancet Neurol 12:84–91. doi:http://dx.doi.org/10.1016/S1474-4422(12)70295-8
Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med 14:504–506
Li J-Y et al (2008) Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 14:501–503
Mendez I et al (2008) Dopamine neurons implanted into people with Parkinson’s disease survive without pathology for 14 years. Nat Med 14:507–509
Politis M et al (2010) Serotonergic neurons mediate dyskinesia side effects in Parkinson’s patients with neural transplants. Sci Transl Med 2:38ra46. doi:10.1126/scitranslmed.3000976
Carta M, Carlsson T, Kirik D, Bjorklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130:1819–1833. Epub 2007 Apr 1823 (2007)
Evans JR, Mason SL, Barker RA (2012) In: Dunnett Stephen B, Anders B (eds) Progress in brain research, vol 200. Elsevier, pp 169–198
Winkler C, Kirik D, Björklund A (2005) Cell transplantation in Parkinson’s disease: how can we make it work? Trends Neurosci 28:86–92. doi:http://dx.doi.org/10.1016/j.tins.2004.12.006
Rosser AE et al (2002) Unilateral transplantation of human primary fetal tissue in four patients with Huntington’s disease: NEST-UK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatry 73:678–685. doi:10.1136/jnnp.73.6.678
Keene CD et al (2009) A patient with Huntington’s disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol 117:329–338. doi:10.1007/s00401-008-0465-0
Bachoud-Lévi A-C et al (2006) Effect of fetal neural transplants in patients with Huntington’s disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 5:303–309. doi:http://dx.doi.org/10.1016/S1474-4422(06)70381-7
Dawson TM, Ko HS, Dawson VL (2010) Genetic animal models of Parkinson’s disease. Neuron 66:646–661
Nguyen HN et al (2011) LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8:267–280
Polo JM et al (2010) Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 28:848–855. doi:http://www.nature.com/nbt/journal/v28/n8/abs/nbt.1667.html#supplementary-information
Lashuel HA et al (2002) α-Synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322(5):1089–1102
Osafune K et al (2008) Marked differences in differentiation propensity among human embryonic stem cell lines. Nat Biotechnol 26:313–315. doi:http://www.nature.com/nbt/journal/v26/n3/suppinfo/nbt1383_S1.html
Lund RJ, Narva E, Lahesmaa R (2012) Genetic and epigenetic stability of human pluripotent stem cells. Nat Rev Genet 13:732–744. doi:http://www.nature.com/nrg/journal/v13/n10/suppinfo/nrg3271_S1.html
Heiskanen A et al (2007) N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells 25:197–202. doi:10.1634/stemcells.2006-0444
Martin MJ, Muotri A, Gage F, Varki A (2005) Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med 11:228–232
Draper JS et al (2004) Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat Biotechnol 22:53–54
Catalina P, et al (2008) Human ESCs predisposition to karyotypic instability: Is a matter of culture adaptation or differential vulnerability among hESC lines due to inherent properties? 7:76
Takahashi K, Narita M, Yokura M, Ichisaka T, Yamanaka S (2009) Human induced pluripotent stem cells on autologous feeders. PLoS One 4:e8067
Gurjala AN, Liu WR, Mogford JE, Procaccini PSA, Mustoe TA (2005) Age-dependent response of primary human dermal fibroblasts to oxidative stress: cell survival, pro-survival kinases, and entrance into cellular senescence. Wound Repair Regen 13:565–575
Awe J et al (2013) Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status. Stem Cell Res Ther 4:87
Karumbayaram S et al (2012) From skin biopsy to neurons through a pluripotent intermediate under good manufacturing practice protocols. Stem Cells Transl Med 1:36–43. doi:10.5966/sctm.2011-0001
Yagi T et al (2011) Modeling familial Alzheimer’s disease with induced pluripotent stem cells. Hum Mol Genet 20:4530–4539. doi:10.1093/hmg/ddr394
Israel MA et al (2012) Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature 482:216–220. doi:http://www.nature.com/nature/journal/v482/n7384/abs/nature10821.html#supplementary-information
Kondo T et al (2013) Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell 12:487–496. doi:http://dx.doi.org/10.1016/j.stem.2013.01.009
Cole GM, Frautschy SA (2006) Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer’s disease mouse model. Nutr Health 18:249–259. doi:10.1177/026010600601800307
Cooper O et al (2012) Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson’s disease. Sci Transl Med 4:141ra190. doi:10.1126/scitranslmed.3003985
Sánchez-Danés A et al (2012) Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson’s disease. EMBO Mol Med 4:380–395. doi:10.1002/emmm.201200215
Sanders LH et al (2013) LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson’s disease patients: Reversal by gene correction. Neurobiol Dis. doi:http://dx.doi.org/10.1016/j.nbd.2013.10.013
Gloeckner CJ et al (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15:223–232. doi:10.1093/hmg/ddi439
West AB et al (2005) Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102:16842–16847. doi:10.1073/pnas.0507360102
Camnasio S et al (2012) The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington’s disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol Dis 46:41–51. doi:http://dx.doi.org/10.1016/j.nbd.2011.12.042
Pearson CE, Edamura KN, Cleary JD (2005) Repeat instability: mechanisms of dynamic mutations. Nat Rev Genet 6:729–742. doi:http://www.nature.com/nrg/journal/v6/n10/suppinfo/nrg1689_S1.html
Cannella M et al (2009) DNA instability in replicating Huntington’s disease lymphoblasts. BMC Med Genet 10:11
Dragileva E et al (2009) Intergenerational and striatal CAG repeat instability in Huntington’s disease knock-in mice involve different DNA repair genes. Neurobiol Dis 33:37–47. doi:http://dx.doi.org/10.1016/j.nbd.2008.09.014
Kennedy L et al (2003) Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet 12:3359–3367. doi:10.1093/hmg/ddg352
Jeon I et al (2012) Neuronal properties, in vivo effects, and pathology of a Huntington’s disease patient-derived induced pluripotent stem cells. Stem Cells 30:2054–2062. doi:10.1002/stem.1135
The HD iPSc Consortium (2012) Induced pluripotent stem cells from patients with Huntington’s disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11:264–278. doi:http://dx.doi.org/10.1016/j.stem.2012.04.027
Egawa N et al (2012) Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 4:145ra104. doi:10.1126/scitranslmed.3004052
Tollervey JR et al (2011) Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci 14:452–458. doi:http://www.nature.com/neuro/journal/v14/n4/abs/nn.2778.html#supplementary-information
Polymenidou M et al (2011) Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14:459–468. doi:http://www.nature.com/neuro/journal/v14/n4/abs/nn.2779.html#supplementary-information
Hagell P et al (2002) Dyskinesias following neural transplantation in Parkinson’s disease. Nat Neurosci 5:627–628
Bohnen NI et al (2013) Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology 81:1611–1616
Fox SH (2013) Non-dopaminergic treatments for motor control in Parkinson’s disease. Drugs 73:1405–1415. doi:10.1007/s40265-013-0105-4
Emre M (2003) Dementia associated with Parkinson’s disease. Lancet Neurol 2:229–237. doi:http://dx.doi.org/10.1016/S1474-4422(03)00351-X
Luk KC et al (2012) Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338:949–953. doi:10.1126/science.1227157
Sandberg MK, Al-Doujaily H, Sharps B, Clarke AR, Collinge J (2011) Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 470:540–542
Frost B, Jacks RL, Diamond MI (2009) Propagation of Tau misfolding from the outside to the inside of a cell. J Biol Chem 284:12845–12852. doi:10.1074/jbc.M808759200
Desplats P et al (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proc Natl Acad Sci 106:13010–13015. doi:10.1073/pnas.0903691106
de Calignon A et al (2012) Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron 73:685–697. doi:http://dx.doi.org/10.1016/j.neuron.2011.11.033
Masuda-Suzukake M et al (2013) Prion-like spreading of pathological α-synuclein in brain. Brain 136:1128–1138. doi:10.1093/brain/awt037
Clavaguera F et al (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11:909–913. doi:http://www.nature.com/ncb/journal/v11/n7/suppinfo/ncb1901_S1.html
Moreno JA et al (2013) Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci Transl Med 5:206ra138. doi:10.1126/scitranslmed.3006767
Juopperi T et al (2012) Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington’s disease patient cells. Mol Brain 5:17
Han J et al (2013) ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat Cell Biol 15:481–490. doi:10.1038/ncb2738, http://www.nature.com/ncb/journal/v15/n5/abs/ncb2738.html#supplementary-information
Kon T et al (2013) ALS-associated protein FIG4 is localized in Pick and Lewy bodies, and also neuronal nuclear inclusions, in polyglutamine and intranuclear inclusion body diseases. Neuropathology 34(1):19–26. doi:10.1111/neup.12056
Wang IF, Wu L-S, Shen CKJ (2008) TDP-43: an emerging new player in neurodegenerative diseases. Trends Mol Med 14:479–485. doi:http://dx.doi.org/10.1016/j.molmed.2008.09.001
Xu Z-S (2012) Does a loss of TDP-43 function cause neurodegeneration? Mol Neurodegeneration 7:27
Nonaka T et al (2013) Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep 4(1):124–134
Wolswijk G (2002) Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. Brain 125:338–349. doi:10.1093/brain/awf031
Shen S et al (2008) Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat Neurosci 11:1024–1034. doi:http://www.nature.com/neuro/journal/v11/n9/suppinfo/nn.2172_S1.html
Payne NL et al (2013) Distinct immunomodulatory and migratory mechanisms underpin the therapeutic potential of human mesenchymal stem cells in autoimmune demyelination. Cell Transplant 22:1409–1425. doi:10.3727/096368912x657620
Bai L et al (2009) Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 57:1192–1203. doi:10.1002/glia.20841
Connick P et al (2012) Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 11:150–156. doi:http://dx.doi.org/10.1016/S1474-4422(11)70305-2
Rice CM et al (2010) Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. Clin Pharmacol Ther 87:679–685. doi:http://www.nature.com/clpt/journal/v87/n6/suppinfo/clpt201044s1.html
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer India
About this chapter
Cite this chapter
Barbuti, P.A. (2014). Stem Cell Therapy for Neurological Disorders: From Bench to Bedside. In: Somasundaram, I. (eds) Stem Cell Therapy for Organ Failure. Springer, New Delhi. https://doi.org/10.1007/978-81-322-2110-4_4
Download citation
DOI: https://doi.org/10.1007/978-81-322-2110-4_4
Published:
Publisher Name: Springer, New Delhi
Print ISBN: 978-81-322-2109-8
Online ISBN: 978-81-322-2110-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)